sections "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in each case included in this prospectus.Unless the context otherwise requires, we use the terms "SteadyMed," "company," "we," "us" and "our" in this prospectus to refer to SteadyMed Ltd. and,
binding agreements or commitments to purchase, so the underwriters could determine to sell no2Table of Contentsshares to any of these potential purchasers and these potential purchasers could determine to purchase no shares in this offering.Following this closing, as of January 31, 2015, we had approximately $16.4 million in cash and cash equivalents (excluding restricted cash of approximately $1 million).Our StrategyWe plan to leverage our proprietary PatchPump technology to develop and commercialize differentiated pharmaceutical products that
PAH patients receiving treprostinil therapy;•Obtain approval for the sale of our AHPA product candidates in the United States;•Secure one or more partners in Europe for the approval and commercialization of Trevyent and our AHPA product candidates;•Expand our product portfolio with additional product candidates that provide significant benefits over market-leading
to compete effectively in our market; and•We may be a passive foreign investment company, which may result in adverse U.S. federal income tax consequences for U.S. Holders of our ordinary shares.Our Corporate InformationWe were incorporated under the laws of Israel in 2005.
offering price of $13.00 per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We currently expect to use the net proceeds from the offering as follows:•Approximately $16.5 million to
Our historical results are not necessarily indicative of the results that should be expected in the future.Year endedDecember 31,201220132014Operating expenses:Research and development$2,745$6,436$12,876Marketing225511928General and administrative1,1741,5741,996​​​​​​​​​​​Total operating loss4,1448,52115,800​​​​​​​​​​​Financial expense (income), net(92)(761)2,995​​​​​​​​​​​Loss before taxes on income4,0527,76018,795​​​​​​​​​​​Taxes on income2897245​​​​​​​​​​​Net loss4,0807,85719,040​​​​​​​​​​​Net loss per share:Basic and diluted net loss per ordinary share$(10.21)$(19.12)$(44.15)​​​​​​​​​​​​​​​​​​​​​​Weighted average number of ordinary shares used in computing basic and diluted net loss per share501,828501,828501,968​​​​​​​​​​​​​​​​​​​​​​Basic and diluted pro forma net loss per ordinary share(1):$(2.81)​​​​​​​​​​​​​​​​​​​​​​Weighted average number of ordinary shares used in computing basic and diluted pro forma net loss per ordinary share(1):6,762,914​​​​​​​​​​​​​​​​​​​​​​As of December 31, 2014ActualPro Forma(2)Pro Forma,As Adjusted(3)(in thousands)(unaudited)Consolidated Balance Sheet Data(4)(5):Cash and cash equivalents$6,167$17,54067,576Working capital2,99714,37064,936Total assets10,32621,69970,262Convertible preferred shares35,669——Total shareholders' equity (deficit)(36,321)16,79265,895(1)Pro
be able to earn sufficient revenues to continue our business.If the FDA does not conclude that Trevyent or our AHPA product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the
ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.The time required to obtain approval by the FDA and comparable authorities outside the United States is unpredictable and typically
facilities of third party manufacturers with which we contract for clinical and commercial supplies; and•the approval policies or regulations of the FDA or comparable regulatory authorities outside the United States may change
effect on our business, financial condition, results of operations and growth prospects.Trevyent may fail to offer material commercial advantages over other injectable prostacyclin therapies.The convenience and possible safety advantages that we believe Trevyent would offer, if approved by regulatory authorities, may fail
such events may result in decreased sales and lower revenue, which could have a material adverse effect on our business, prospects, financial condition and results of operations.18Table of ContentsCoverage and reimbursement may not be available, or may be available at only limited levels, for our product candidates, which could make it difficult for us to sell our
international operations could materially adversely affect our business, including:•different regulatory requirements for drug approvals in countries outside the United States;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•non-U.S. taxes, including withholding of payroll taxes;20Table of Contents•foreign currency fluctuations, which could result in increased operating expenses and reduced revenue and other
attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile.Our limited operating history makes evaluating our business and future prospects difficult, and may increase the risk of any investment in our ordinary shares.Our operations to date have been limited to developing Trevyent and our other product candidates.
compliance with applicable federal and state privacy, security and fraud laws may prove costly.Our product candidates may cause serious adverse side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of
arrangements, pursuant to which we would seek to obtain contractual indemnification protection from such third-party manufacturers potentially limiting this liability exposure.Business interruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.Our operations could be subject to earthquakes, power shortages, telecommunications failures, systems failures, water shortages,
have a material adverse effect on our business, operating results and prospects.Our independent registered public accounting firm has expressed doubt about our ability to continue as a going concern.We are an early stage company, and the development and commercialization of our product is uncertain and expected to require
Considerations and Government Programs — Tax Benefits under the Law for the Encouragement of Capital Investments, 5719-1959."Risks Related to Intellectual PropertyIf we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete effectively in our market.As of December 31, 2014, our intellectual property portfolio included three issued U.S. patents and 13 issued foreign patents,
United States;•our ability to scale up and secure manufacturing and distribution capability for our product candidates, if approved;•our estimates of our expenses, future revenue, capital requirements and our needs for additional financing;•our implementation of our business model, strategic plans for our business, product candidates and technology;•our expectations regarding the timing, progress and results of our research and development programs;•the scope of protection we are able to establish and maintain for intellectual property rights covering our product